REFERENCES


- Brunner HR. 2001. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol, 87:3C-9C.


bioequivalence studies based on population and individual bioequivalence approaches. CDER, Food and Drug Administration, October 1997. Available at: http://www.fda.gov/ohrms/dockets/98fr/090899c.txt.


➢ Dubovsky SL. Severe nortriptyline intoxication due to change from a generic to a trade preparation. J Nerv Ment Dis. 1987; 175:115-117.


➢ Ethical guidelines for biomedical research on human participants Indian council of medical research New Delhi 2006


Peng chai et al. Intersubject Variability in Pharmacokinetics and Subject Characteristics in Phase I studies.


Marco Antônio Mota Gomes, Audes Diógenes de Magalhães Feitosa, Wille Oigman, José Márcio Ribeiro, Based treatment algorithm for essential hypertension with olmesartan medoxomil Arq Bras Cardiol 2008;91(3):168-176.
- J. Bras. Nefrol Meta-analysis for bioequivalence studies: interchangeability of generic drugs and similar containing Hydrochlorothiazide is possible but not with Enalapril Maleate. Jornal Brasileiro de Nefrologia. vol.32 no.2 São Paulo Apr./June 2010


- Rana, Rajiv, Singh, Amarinder Olmesartan medoxomil evaluated for safety and efficacy in Indian patients with essential hypertension: a real world observational postmarketing surveillance The Journal of the Association of Physicians of India 02/2010; 58; 77-82.


SPC (Summary product Characteristics) OLMETEC® 40 mg film coated tablet 2009.


Time to effectively address hypertension in India. Indian J Med Res 137, April 2013, pp 627-631


Wyllie E, Pippenger CE, Rothner AD. Increased seizure frequency with generic primidone. JAMA 1987; 258:1216-1217.


Zuzanna Fimińska Doctors in India Unlikely to Follow Guidelines on Generic Drugs - O eye for Pharma July 02 2013